RHEUMATOLOGY / CLINICAL RESEARCH
Kawasaki disease in Latvia 2012–2019: epidemiology and rate of resistance to initial treatment
More details
Hide details
1
Children’s Clinical University Hospital, Latvia
2
Riga Stradiņš University, Latvia
Submission date: 2020-05-14
Final revision date: 2020-06-17
Acceptance date: 2020-07-05
Online publication date: 2020-11-04
Publication date: 2026-02-28
Corresponding author
Lauma Vasiļevska
Children’s Clinical University Hospital
45 Vienibas gatve
Riga, Latvia, LV-1004
Arch Med Sci 2026;22(1):175-178
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Kawasaki disease (KD) is an acute febrile illness of early childhood, characterised by vasculitis of the coronary and medium-sized arteries. The incidence of the disease differs worldwide, but the incidence of KD has not been established in Latvia. The aim of the study was to describe the epidemiological characteristics and estimate the incidence rate and resistance to initial treatment of KD among hospitalised children in Latvia.
Material and methods:
The study was a descriptive, population-based study, which used hospital discharge records of patients < 18 years old diagnosed with KD in the years 2012–2019. Incidence rate was calculated using the number of KD patients and corresponding national census data.
Results:
There were 36 KD patients in Latvia. The median age at admission was 2.8 years, with 67% of cases under 5 years of age, and the male/female ratio was 1.3 : 1. The mean annual incidence rate was 1.3 per 100,000 children 0–18 years old, and 2.9 per 100,000 for children < 5 years old. The mean length of hospital stay was 14 days. Coronary artery dilatation was recorded in 8% of the patients (all of whom were male). Every patient received intravenous immunoglobulin (IVIG), with a median of 7 days from fever onset to IVIG administration. Refractory treatment was reported in 25% of cases.
Conclusions:
This is the first epidemiological study of KD in Latvia. The incidence rates are lower than those reported for other European countries. The percentage of refractory treatment was higher than in other studies.
REFERENCES (18)
1.
Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364: 533-44.
2.
McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation 2017; 135: 927-99.
3.
Sundel R. Kawasaki disease: clinical features and diagnosis. In: Post TW (ed.). UpToDate. Waltham MA: UpToDate; 2020.
4.
Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-7.
5.
Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708-33.
6.
Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606-12.
7.
Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149: 237-40.
8.
Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613-20.
9.
Salo E. Kawasaki disease epidemiology in Europe. In: Saji BT, Newburger JW, Burns JC, Takakashi M (eds.). Kawasaki disease. Tokyo: Springer; 2017; 88-89.
10.
Salo E, Griffiths EP, Farstad T, et al. Incidence of Kawasaki disease in northern European countries. Pediatr Int 2012; 54: 770-2.
11.
Son MBF, Newburger JW. Kawasaki disease. Pediatr Rev 2018; 39: 78-90.
12.
Dominguez SR, Anderson MS, El-Adawy M, Glodé MP. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease. Pediatr Infect Dis J 2012; 31: 1217-20.
13.
Printz BF, Sleeper LA, Newburger JW, et al. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol 2011; 57: 86-92.
14.
Tang Y, Gao X, Shen J, Sun L, Yan W. Epidemiological and clinical characteristics of Kawasaki disease and factors associated with coronary artery abnormalities in east China: nine years’ experience. J Trop Pediatr 2016; 62: 86-93.
15.
Kimberlin DW, Brady MT, Jackson MA, Long SS (eds.). Red book: Report of the Committee on Infectious Diseases. 31st ed. Itasca: American Academy of Pediatrics; 2018, pp. 490-7.
16.
Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158: 831-5.
17.
Davies S, Sutton N, Blackstock S, et al. Predicting IVIG resistance in UK Kawasaki disease. Arch Dis Child 2015; 100: 366-8.
18.
Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child 2014; 99: 74-83.